NASDAQ:GLPG
Galapagos NV Stock News
$29.80
-0.450 (-1.49%)
At Close: Apr 15, 2024
Galapagos en CellPoint hebben op ASH 2022 bemoedigende eerste data gepresenteerd van GLPG5101, een CD19 CAR-T-kandidaat die point-of-care wordt geproduceerd
06:00am, Tuesday, 13'th Dec 2022 GlobeNewswire Inc.
Mechelen, België; 13 december 2022, 7.00 CET; Galapagos NV (Euronext & NASDAQ: GLPG) en CellPoint (een Galapagos bedrijf) hebben vandaag op het 64th Annual American Society of Hematology (ASH) Congre
Down 5.9% in 4 Weeks, Here's Why Galapagos NV (GLPG) Looks Ripe for a Turnaround
02:35pm, Thursday, 08'th Dec 2022 Zacks Investment Research
Galapagos NV (GLPG) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estima
Down 5.9% in 4 Weeks, Here's Why Galapagos NV (GLPG) Looks Ripe for a Turnaround
11:17am, Thursday, 08'th Dec 2022
Galapagos NV (GLPG) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estima
Galapagos kondigt aan dat het CHMP de aanbeveling van het PRAC voor Jyseleca® heeft overgenomen na een uitgebreide veiligheidsbeoordeling van alle JAK-remmers
12:15pm, Friday, 11'th Nov 2022 GlobeNewswire Inc.
Mechelen, België; 11 november 2022, 13.15 CET; Galapagos NV (Euronext & NASDAQ: GLPG) heeft vandaag aangekondigd dat het Comité voor geneesmiddelen voor menselijk gebruik (CHMP), het wetenschappeli
Galapagos announces CHMP adoption of PRAC’s recommendation for Jyseleca® following extensive safety review of all JAK inhibitors
12:15pm, Friday, 11'th Nov 2022 GlobeNewswire Inc.
Mechelen, Belgium; 11 November 2022, 13.15 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee
Galapagos to present encouraging initial data from FILOSOPHY real-world arthritis study at ACR Convergence 2022
04:01pm, Tuesday, 08'th Nov 2022
Mechelen, Belgium; 8 November 2022, 22.01 CET, Galapagos NV (Euronext & NASDAQ: GLPG) will present new data on filgotinib at the American College of Rheumatology ( ACR ) Co n vergence 2022 meeting tak
Benzinga's Top Ratings Upgrades, Downgrades For November 7, 2022
02:25pm, Monday, 07'th Nov 2022 Benzinga
Upgrades
Guggenheim upgraded the previous rating for Okta Inc (NASDAQ:OKTA) from Neutral to Buy. For the second quarter, Okta had an EPS of $0.10, compared to year-ago quarter EPS of $0.11. The curren
Galapagos presenteert stappenplan voor pijplijn- en commerciële groei op haar R&D-dag 2022
08:01pm, Friday, 04'th Nov 2022 GlobeNewswire Inc.
Webcast replay beschikbaar op www.glpg.com
Galapagos presents roadmap for pipeline and commercial growth at its R&D Day 2022
08:01pm, Friday, 04'th Nov 2022 GlobeNewswire Inc.
Webcast replay available at www.glpg.com
Galapagos organiseert haar R&D Update 2022 in New York op 4 november 2022
05:30am, Monday, 17'th Oct 2022 GlobeNewswire Inc.
Mechelen, België; 17 oktober 2022, 07.30 CET; – Galapagos NV (Euronext & NASDAQ: GLPG) kondigt vandaag aan dat het op vrijdag 4 november 2022 haar R&D Update 2022 voor analisten, investeerders en f
Galapagos to host its R&D Update 2022 in New York on 4 November 2022
05:30am, Monday, 17'th Oct 2022 GlobeNewswire Inc.
Mechelen, Belgium; 17 October 2022, 07.30 CET; - Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will host its R&D Day 2022 for analysts, investors and financial press on Friday, 4 Nove
Expert Ratings for Galapagos
02:05pm, Thursday, 13'th Oct 2022 Benzinga
Over the past 3 months, 4 analysts have published their opinion on Galapagos (NASDAQ:GLPG) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a compa
Galapagos: Trading At Discount To Cash With A Fast-Growing Marketed Product
01:16pm, Monday, 10'th Oct 2022
Galapagos has had a new CEO since April 2022. The company's new strategy is taking shape with some research programs scrapped and small assets acquired.
Galapagos ontvangt positief CHMP-advies voor update van het Europees label voor Jyseleca® gebaseerd op testiculaire functie veiligheidsgegevens van MANTA/RAy studies
08:01pm, Monday, 03'rd Oct 2022 GlobeNewswire Inc.
Type II wijziging1 regelgevingsaanvraag tot wijziging van de Europese productinformatie van Jyseleca® (filgotinib) op basis van gegevens uit de MANTA- en MANTA-RAy-studies bij patiënten met respecti
Galapagos receives positive CHMP opinion for Jyseleca® European label update based on testicular function safety data from MANTA/RAy studies
08:01pm, Monday, 03'rd Oct 2022 GlobeNewswire Inc.
Type II variation1 regulatory application to amend the European label of Jyseleca® (filgotinib) based on data from MANTA and MANTA-RAy studies in patients with inflammatory bowel disease (IBD) and rh
